Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...

Over the last year, Metsera Inc share price has been traded in a range of 3.00, hitting a high of 28.60, and a low of 25.60. Metsera Inc is listed on the CBOE trading with ticker code MTSR.US.

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Sionna is working out its IPO plans days after obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics both listed on the Nasdaq with offerings of $275 million and $140 million ...

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs. Just nine months after emerging from stealth with a $290 million Series A ...

Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

and newly public Metsera (MTSR). Other companies, such as Arrowhead Pharmaceuticals (NASDAQ:ARWR), are developing drugs with different mechanisms of action. And Allurion Technologies (ALUR ...

A Pfizer drug recently awarded accelerated FDA approval in colorectal cancer now has additional data showing it met key goals in its pivotal study, results that could support an application ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.